基于KEAP1的PROTAC作为新兴治疗模式的进展:结构基础和进展
Jing Chen1, Disheng Feng2, Rui Zhu1
1Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Redox biology
|July 27, 2025
概括
凯尔克类ECH相关蛋白1 (KEAP1) 是细胞氧化还原平衡的关键调节者. 新的蛋白质溶解向金马 (PROTACs) 利用KEAP1降解与疾病相关的蛋白质,提供了一个有前途的治疗途径.
科学领域:
- 生物化学和分子生物学
- 药物发现和开发 药物发现和开发
- 细胞生物学 细胞生物学
背景情况:
- 凯尔奇类ECH相关蛋白1 (KEAP1) 作为Cullin 3-RING E3结合酶的基质适配剂,准核因子红色素2相关因子2 (NRF2) 进行蛋白质体降解.
- 这种调节对于通过防止NRF2过度激活来维持细胞氧化还原平衡至关重要.
研究的目的:
- 提供KEAP1的结构,功能和与NRF2和Cullin3的相互作用的全面审查.
- 讨论KEAP1招募蛋白质解析向化马体 (PROTACs) 针对蛋白质降解的发展和潜力.
- 突出基于KEAP1的向蛋白质降解策略的近期进展和挑战.
主要方法:
- 对KEAP1结构,功能和相互作用的现有文献的审查.
- 基于KEAP1的PROTAC开发的分析,包括各种连接物类 (,共价,非共价抑制剂).
- 检查基于KEAP1的特定PROTACs,针对BRD4,CDK9,FAK,Tau和KEAP1本身等蛋白质.
主要成果:
- KEAP1是PROTACs的一种多功能E3酶招募剂,具有多种抑制剂衍生联体,增强其效用.
- 基于KEAP1的PROTAC在降解各种标蛋白质方面表现有前途,目前正在努力优化连接体以提高有效性和特异性.
- 对KEAP1相互作用的结构洞察力对于推进PROTAC设计至关重要.
结论:
- KEAP1代表了对PROTAC开发的有前途的E3结合酶,提供了多样化的招聘策略.
- 需要进一步的研究来克服基于KEAP1的向蛋白质降解的当前挑战,并优化连接体特性.
- 探索KEAP1介导降解的新型蛋白质标可以显著推进这种治疗方式.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


